Epigenetic risk score improves prostate cancer risk assessment

Early detection of aggressive prostate cancer (PCa) remains crucial for effective treatment of patients. However, PCa screening remains controversial due to a high rate of overdiagnosis and overtreatment. To better reconcile both objectives, more effective methods for assessing disease severity at the time of diagnosis are needed.

[1]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[2]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[3]  C. von Bodman,et al.  Comprehensive report on prostate cancer misclassification by 16 currently used low‐risk and active surveillance criteria , 2012, BJU international.

[4]  E. Platz,et al.  GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer. , 2014, The Journal of urology.

[5]  Wim Van Criekinge,et al.  Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. , 2013, The Journal of urology.

[6]  J. Herman,et al.  The Epigenetic promise for prostate cancer diagnosis , 2012, The Prostate.

[7]  Bruce J Trock,et al.  Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. , 2012, European urology.

[8]  A. Laurinavičius,et al.  Prognostic value of RASSF1 promoter methylation in prostate cancer. , 2014, The Journal of urology.

[9]  P. Stattin,et al.  Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer. , 2014, The Journal of urology.

[10]  K. Badani,et al.  Delay from biopsy to radical prostatectomy influences the rate of adverse pathologic outcomes , 2015, The Prostate.

[11]  J. Epstein,et al.  Quantitative GSTP1 methylation levels correlate with Gleason grade and tumor volume in prostate needle biopsies. , 2004, The Journal of urology.

[12]  L. van Neste,et al.  Reduced Rate of Repeated Prostate Biopsies Observed in ConfirmMDx Clinical Utility Field Study. , 2014, American health & drug benefits.

[13]  F. Montorsi,et al.  Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. , 2015, European urology.

[14]  A. Carvalho,et al.  High Promoter Methylation Levels of APC Predict Poor Prognosis in Sextant Biopsies from Prostate Cancer Patients , 2007, Clinical Cancer Research.

[15]  J. Weedon,et al.  Prostate biopsy concordance in a large population-based sample: a Surveillance, Epidemiology and End Results study , 2015, Journal of Clinical Pathology.

[16]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[17]  A. Mazumder,et al.  Quantitative, spatial resolution of the epigenetic field effect in prostate cancer , 2008, The Prostate.

[18]  Theodorus H van der Kwast,et al.  The contemporary concept of significant versus insignificant prostate cancer. , 2011, European urology.

[19]  J. Epstein,et al.  A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection , 2012, BMC Urology.

[20]  Monique J. Roobol,et al.  Defining the threshold for significant versus insignificant prostate cancer , 2013, Nature Reviews Urology.

[21]  A. D'Amico,et al.  Prostate cancer, version 2.2014. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[22]  T. Jatkoe,et al.  A urine-based methylation signature for risk stratification within low-risk prostate cancer , 2015, British Journal of Cancer.

[23]  Liying Zhang,et al.  Gleason Upgrading with Time in a Large Prostate Cancer Active Surveillance Cohort. , 2015, The Journal of urology.

[24]  G. Sauter,et al.  Heterogeneity in D'Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility. , 2015, Urologic oncology.

[25]  G. Andriole.  Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. , 2014, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[26]  T. Choueiri,et al.  Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. , 2015, The Journal of urology.

[27]  M. Chancellor,et al.  Intraprostatic injection of botulinum toxin type- A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs , 2006, BMC urology.

[28]  A. Partin,et al.  Risk score predicts high‐grade prostate cancer in DNA‐methylation positive, histopathologically negative biopsies , 2016, The Prostate.

[29]  M. Rubin,et al.  Tissue-print and print-phoresis as platform technologies for the molecular analysis of human surgical specimens: mapping tumor invasion of the prostate capsule , 2005, Nature Medicine.

[30]  V. Fiano,et al.  Methylation of APC and GSTP1 in Non-Neoplastic Tissue Adjacent to Prostate Tumour and Mortality from Prostate Cancer , 2013, PloS one.

[31]  T. Guzzo,et al.  Repeat prostate biopsy and the incremental risk of clinically insignificant prostate cancer. , 2010, Urology.

[32]  Olof Akre,et al.  Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  B. Trock,et al.  Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. , 2014, The Journal of urology.

[34]  David C. Miller,et al.  Prostate Cancer,,Version 2.2014 Clinical Practice Guidelines in Oncology , 2014 .

[35]  Hafiz Ahmed.  Promoter Methylation in Prostate Cancer and its Application for the Early Detection of Prostate Cancer Using Serum and Urine Samples , 2010, Biomarkers in cancer.